+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Beta Thalassemia Testing Market by Test Type, End User, Technology - Global Forecast 2025-2030- Product Image
Beta Thalassemia Testing Market by Test Type, End User, Technology - Global Forecast 2025-2030- Product Image
Sale

Beta Thalassemia Testing Market by Test Type, End User, Technology - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6013877
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Beta Thalassemia Testing Market grew from USD 446.83 million in 2023 to USD 478.47 million in 2024. It is expected to continue growing at a CAGR of 8.37%, reaching USD 784.35 million by 2030.

Beta Thalassemia Testing is crucial for the diagnosis and management of Beta Thalassemia, a genetic blood disorder that reduces the production of hemoglobin. Given the implications for patient quality of life and life expectancy, accurate testing is vital. The necessity for Beta Thalassemia Testing stems from genetic counseling, prenatal screening, and patient management, with applications across hospitals, diagnostic centers, and research laboratories. The end-use scope extends to secondary and tertiary healthcare institutions, enhancing their diagnostic capabilities. Market growth is influenced by advancements in genetic testing technologies and increased prevalence of hereditary disorders. The rising awareness and need for early diagnosis further propel demand. Regions with higher genetic disorder prevalence, such as the Mediterranean, Middle Eastern, and Southeast Asian countries, present key growth opportunities. There's a burgeoning potential in the integration of AI in genetic analytics, enhancing diagnostic accuracy and efficiency. Marketing strategies focusing on partnerships with healthcare facilities can capitalize on these opportunities.

However, several challenges hinder market growth. High costs associated with advanced genetic testing technologies and inadequate healthcare infrastructure in developing countries limit accessibility and affordability. Additionally, variability in regulatory standards across regions can delay product approvals and market entry. Overcoming these hurdles requires innovation in cost-effective testing solutions and standardization of regulatory guidelines. Areas ripe for innovation include the development of rapid and non-invasive testing techniques and improvements in digital health platforms for better patient data management. Research into CRISPR and gene therapy opens another frontier for the market, offering potential therapeutic applications beyond mere diagnostics. The market is dynamic, with a competitive landscape characterized by key players focusing on technological advancements and strategic collaborations. Staying abreast of advancements in personalized medicine and leveraging biotechnological innovations presents the best pathway for sustained business growth and market leadership in Beta Thalassemia Testing.

Understanding Market Dynamics in the Beta Thalassemia Testing Market

The Beta Thalassemia Testing Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of beta thalassemia worldwide driving demand for specialized testing methods
    • Rising awareness and government initiatives for early detection and management of beta thalassemia
    • Expansion of healthcare infrastructure in developing regions providing access to beta thalassemia testing
  • Market Restraints
    • High costs of advanced testing technologies associated with advanced diagnostic technologies
  • Market Opportunities
    • Development of cost-effective testing methods enabling widespread adoption of beta thalassemia screening
    • Rising public awareness and government initiatives promoting beta thalassemia testing and management
    • Collaborations between healthcare providers and biotech firms facilitating beta thalassemia test advancements
  • Market Challenges
    • Limited access to specialized healthcare facilities in rural and underdeveloped regions for beta thalassemia testing

Exploring Porter’s Five Forces for the Beta Thalassemia Testing Market

Porter’s Five Forces framework further strengthens the insights of the Beta Thalassemia Testing Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Beta Thalassemia Testing Market

External macro-environmental factors deeply influence the performance of the Beta Thalassemia Testing Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Beta Thalassemia Testing Market

The Beta Thalassemia Testing Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Beta Thalassemia Testing Market

The Beta Thalassemia Testing Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Beta Thalassemia Testing Market

The Beta Thalassemia Testing Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Beta Thalassemia Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, Asuragen, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., bioMérieux SA, Cepheid, F. Hoffmann-La Roche Ltd., GenMark Diagnostics, Illumina, Inc., Immucor, Inc., Luminex Corporation, PerkinElmer, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Trinity Biotech.

Market Segmentation & Coverage

This research report categorizes the Beta Thalassemia Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Test Type
    • Carrier Screening
    • Diagnostic Testing
      • Genetic Testing
      • Hematological Testing
    • Newborn Screening
    • Prenatal Testing
      • Invasive Prenatal Testing
      • Non-Invasive Prenatal Testing (NIPT)
  • End User
    • Diagnostic Laboratories
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Technology
    • Microarray Technology
    • Next-Generation Sequencing (NGS)
    • PCR (Polymerase Chain Reaction)
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of beta thalassemia worldwide driving demand for specialized testing methods
5.1.1.2. Rising awareness and government initiatives for early detection and management of beta thalassemia
5.1.1.3. Expansion of healthcare infrastructure in developing regions providing access to beta thalassemia testing
5.1.2. Restraints
5.1.2.1. High costs of advanced testing technologies associated with advanced diagnostic technologies
5.1.3. Opportunities
5.1.3.1. Development of cost-effective testing methods enabling widespread adoption of beta thalassemia screening
5.1.3.2. Rising public awareness and government initiatives promoting beta thalassemia testing and management
5.1.3.3. Collaborations between healthcare providers and biotech firms facilitating beta thalassemia test advancements
5.1.4. Challenges
5.1.4.1. Limited access to specialized healthcare facilities in rural and underdeveloped regions for beta thalassemia testing
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Beta Thalassemia Testing Market, by Test Type
6.1. Introduction
6.2. Carrier Screening
6.3. Diagnostic Testing
6.3.1. Genetic Testing
6.3.2. Hematological Testing
6.4. Newborn Screening
6.5. Prenatal Testing
6.5.1. Invasive Prenatal Testing
6.5.2. Non-Invasive Prenatal Testing (NIPT)
7. Beta Thalassemia Testing Market, by End User
7.1. Introduction
7.2. Diagnostic Laboratories
7.3. Hospitals
7.4. Research Institutes
7.5. Specialty Clinics
8. Beta Thalassemia Testing Market, by Technology
8.1. Introduction
8.2. Microarray Technology
8.3. Next-Generation Sequencing (NGS)
8.4. PCR (Polymerase Chain Reaction)
9. Americas Beta Thalassemia Testing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Beta Thalassemia Testing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Beta Thalassemia Testing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BETA THALASSEMIA TESTING MARKET RESEARCH PROCESS
FIGURE 2. BETA THALASSEMIA TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. BETA THALASSEMIA TESTING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. BETA THALASSEMIA TESTING MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BETA THALASSEMIA TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BETA THALASSEMIA TESTING MARKET DYNAMICS
TABLE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HEMATOLOGICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING (NIPT), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 43. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 44. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 45. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 46. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 48. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 49. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 50. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 51. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 70. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 71. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 72. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 73. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 76. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 77. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 78. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 86. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 87. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 88. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 116. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 117. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 118. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 131. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 132. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 133. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 134. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 137. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 138. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 139. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 141. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 142. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 143. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 144. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 148. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 149. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 151. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 153. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 154. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 162. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 163. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 164. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 177. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 178. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 179. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 182. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 183. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 184. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 187. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 188. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 189. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 208. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 209. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 223. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 224. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 236. BETA THALASSEMIA TESTING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 237. BETA THALASSEMIA TESTING MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Beta Thalassemia Testing market, which are profiled in this report, include:
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ARUP Laboratories
  • Asuragen, Inc.
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • bioMérieux SA
  • Cepheid
  • F. Hoffmann-La Roche Ltd.
  • GenMark Diagnostics
  • Illumina, Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 478.47 Million
Forecasted Market Value ( USD ) by 2030 $ 784.35 Million
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Adult Hemoglobinopathy Testing Market by Group, Type, End-Use - Global Forecast 2025-2030 - Product Image

Adult Hemoglobinopathy Testing Market by Group, Type, End-Use - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Hemoglobin Testing Market by Type, Technology, Operation, Application, End-User - Global Forecast 2025-2030 - Product Image

Hemoglobin Testing Market by Type, Technology, Operation, Application, End-User - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
South & Central America Coagulation Market Forecast to 2030 - Regional Analysis - by Disease Indications, Type, Technology, and End User - Product Image

South & Central America Coagulation Market Forecast to 2030 - Regional Analysis - by Disease Indications, Type, Technology, and End User

  • Report
  • 95 Pages
From
Asia Pacific Coagulation Market Forecast to 2030 - Regional Analysis - by Disease Indications, Type, Technology, and End User - Product Image

Asia Pacific Coagulation Market Forecast to 2030 - Regional Analysis - by Disease Indications, Type, Technology, and End User

  • Report
  • 113 Pages
  • Asia Pacific
From
D-dimer Testing Market Size, Share & Trends Analysis Report by Product, Test Type (Clinical Laboratory, POC), Method (ELISA, LETIA, FIA), Application (DVT, PE, DIC), End-use, Region, and Segment Forecasts, 2025-2030 - Product Image

D-dimer Testing Market Size, Share & Trends Analysis Report by Product, Test Type (Clinical Laboratory, POC), Method (ELISA, LETIA, FIA), Application (DVT, PE, DIC), End-use, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From

About the Beta Thalassemia Testing Market

Beta Thalassemia Testing is a diagnostic test used to detect the presence of the genetic disorder beta thalassemia. The test is used to diagnose the condition in individuals who have a family history of the disorder, or who have symptoms that may indicate the presence of the disorder. The test is typically performed using a blood sample, which is analyzed for the presence of abnormal hemoglobin levels. The test can also be used to determine the severity of the disorder, as well as to monitor the effectiveness of treatment. The Beta Thalassemia Testing market is a growing segment of the Diagnostics industry, with a wide range of products and services available to meet the needs of patients and healthcare providers. Companies in the market include Abbott, Bio-Rad, Siemens, Roche, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.